Hypoxia-inducible factors: cancer progression and clinical translation

Abstract

Hypoxia-inducible factors (HIFs) are master regulators of oxygen homeostasis that match O2 supply and demand for each of the 50 trillion cells in the adult human body. Cancer cells co-opt this homeostatic system to drive cancer progression. HIFs activate the transcription of thousands of genes that mediate angiogenesis, cancer stem cell specification, cell motility, epithelial-mesenchymal transition, extracellular matrix remodeling, glucose and lipid metabolism, immune evasion, invasion, and metastasis. In this Review, the mechanisms and consequences of HIF activation in cancer cells are presented. The current status and future prospects of small-molecule HIF inhibitors for use as cancer therapeutics are discussed.

References 177

1. 1.

   Raymond J, Segre D. The effect of oxygen on biochemical networks and the evolution of complex life. Science. 2006;311(5768):1764-1767.

   Not in our library10.1126/science.1118439

2. 2.

   Braun RD, et al. Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. Am J Physiol Heart Circ Physiol. 2001;280(6):2533-2544.

   Not in our library10.1152/ajpheart.2001.280.6.h2533

3. 3.

   Vaupel P, et al. Oxygenation status of malignant tumors vs. normal tissues: critical evaluation and updated data source based on direct measurements with pO2 microsensors. Appl Magn Reson. 2021;52:1451-1479.

   Not in our library10.1007/s00723-021-01383-6

4. 4.

   Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664-3671.

   Not in our library10.1172/jci67230

5. 5.

   Kierans SJ, Taylor CT. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J Physiol. 2021;599(1):23-37.

   Not in our library10.1113/jp280572

6. 6.

   Semenza GL. Breakthrough science: hypoxia-inducible factors, oxygen sensing, and disorders of hematopoiesis. Blood. 2022;139(16):2441-2449.

   Not in our library10.1182/blood.2021011043

7. 7.

   Watts D, et al. Hypoxia pathway proteins are master regulators of erythropoiesis. Int J Mol Sci. 2020;21(21):8131.

   Not in our library10.3390/ijms21218131

8. 8.

   Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodeling. Cardiovasc Res. 2010;86(2):236-242.

   Not in our library10.1093/cvr/cvq045

9. 9.

   Rodriguez D, et al. Hypoxia pathway proteins and their impact on the blood vasculature. Int J Mol Sci. 2021;22(17):9191.

   Not in our library10.3390/ijms22179191

10. 10.

    Wang Y, et al. Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization. Sci Adv. 2021;7(35):eabe3771.

    Not in our library10.1126/sciadv.abe3771

11. 11.

    Semenza GL, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996;271(51):32529-32537.

    Not in our library10.1074/jbc.271.51.32529

12. 12.
    Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia · 2014

    No notice
13. 13.

    Cavadas MA, et al. The regulation of transcriptional repression in hypoxia. Exp Cell Res. 2017;356(2):173-181.

    Not in our library10.1016/j.yexcr.2017.02.024

14. 14.

    Schödel J, et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011;117(23):e207-e217.

    Not in our library10.1182/blood-2010-10-314427

15. 15.

    Zhang C, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016;113(14):2047-2056.

    Not in our library10.1073/pnas.1602883113

16. 16.

    Semenza GL. The genomics and genetics of oxygen homeostasis. Annu Rev Genomics Hum Genet. 2020;21:183-204.

    Not in our library10.1146/annurev-genom-111119-073356

17. 17.

    Lando D, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002;16(12):1466-1471.

    Not in our library10.1101/gad.991402

18. 18.

    Mahon PC, et al. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15(20):2675-2686.

    Not in our library10.1101/gad.924501

19. 19.

    Gale DP, et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF-2α mutation. Blood. 2008;112(3):919-921.

    Not in our library10.1182/blood-2008-04-153718

20. 20.

    Gordeuk VR, et al. Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. Haematologica. 2020;105(3):e87-e90.

    Not in our library10.3324/haematol.2019.216267

21. 21.

    Bosch-Marcé M, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res. 2007;101(12):1310-1318.

    Not in our library10.1161/circresaha.107.153346

22. 22.

    Vaupel P, et al. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007;9(8):1221-1235.

    Not in our library10.1089/ars.2007.1628

23. 23.

    Bos R, et al. Levels of hypoxia-inducible factor 1α during breast carcinogenesis. J Natl Cancer Inst. 2001;93(4):309-314.

    Not in our library10.1093/jnci/93.4.309

24. 24.
    The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy · 1955

    No notice
25. 25.

    Aebersold DM, et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61(7):2911-2916.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    Krieg M, et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435-5443.

    Not in our library10.1038/sj.onc.1203938

28. 28.

    Zhong H, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59(22):5830-5835.

    Not in our library

29. 29.

    Ravi R, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 2000;14(1):34-44.

    Not in our library10.1101/gad.14.1.34

30. 30.

    Zhong H, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60(6):1541-1545.

    Not in our library

31. 31.

    Zundel W, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14(4):391-396.

    Not in our library10.1101/gad.14.4.391

32. 32.

    Laughner E, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21(12):3995-4004.

    Not in our library10.1128/mcb.21.12.3995-4004.2001

33. 33.

    Zhang Q, et al. Role of hypoxia-inducible factor-1 in cancer stem cells. Mol Med Rep. 2021;23(1):17.

    Not in our library10.3892/mmr.2020.11655

34. 34.
    Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer · 2021

    No notice
35. 35.

    De Heer EC, et al. HIFs, angiogenesis and metabolism: elusive enemies in breast cancer. J Clin Invest. 2020;130(10):5074-5087.

    Not in our library10.1172/jci137552

36. 36.

    Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2(12):758-770.

    Not in our library10.1016/j.trecan.2016.10.016

37. 37.

    Semenza GL. Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors. Physiology (Bethesda). 2021;36(2):73-83.

    Not in our library10.1152/physiol.00034.2020

38. 38.

    Xiang L, Semenza GL. Hypoxia-inducible factors promoter breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. Adv Cancer Res. 2019;141:175-212.

    Not in our library10.1016/bs.acr.2018.11.001

39. 39.

    Cowman SJ, Koh MY. Revisiting the HIF switch in the tumor and its immune microenvironment. Trends Cancer. 2022;8(1):28-42.

    Not in our library10.1016/j.trecan.2021.10.004

40. 40.
    Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges · 2019

    No notice

Cited by papers we hold 4

• Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer · 2024
  No notice
• Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions · 2023
  No notice
• Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer · 2023
  No notice
• The role of lipid metabolic reprogramming in tumor microenvironment · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.